Interoperability

HEALTH POLICY BRIEF — Monday, September 21

Three federal policy windows are now on the clock: Medicaid drug pricing, the next generation of interoperability data, and standards for medical imaging…

Matt Reid

— 3 min read
Share

Executive Briefing

Three federal policy windows are now on the clock: Medicaid drug pricing, the next generation of interoperability data, and standards for medical imaging and devices. The deadlines differ, but the pressure point is the same: shape implementation before states, vendors, and technical bodies quietly decide how much friction reaches physicians.

CMS has moved GENEROUS from model design toward state execution—but its public documentation is lagging the announcement. CMS reported Friday that all 50 states, D.C., and Puerto Rico applied to the voluntary Medicaid drug-rebate model; 40 states and Puerto Rico had signed agreements, and remaining states have until September 30. The model page still says “Stage: Announced” and “Participants: N/A,” so the participation release is ahead of the implementation detail. Do not count projected savings or access gains as results yet. Physician policy angle: watch whether state coverage criteria, managed-care formularies, or prior-authorization workflows change, and insist that states, plans, and manufacturers—not practices—carry the operational and notice burden. Monitor: map signatory states, participating manufacturers, covered drugs, and access safeguards as CMS publishes them. Sources: CMS, “CMS Announces Participants in Landmark Medicaid Drug Payment Model,” Sept. 18, 2026 (https://www.cms.gov/newsroom/press-releases/cms-announces-participants-landmark-medicaid-drug-payment-model-bring-down-drug-costs-most) and GENEROUS Model page (https://www.cms.gov/priorities/innovation/innovation-models/generous).

ONC has created a one-week opening on future USCDI versions. USCDI Version 7 was published July 23 with 31 new data elements; ONC is accepting new-element submissions and comments on existing elements through September 28 at 11:59 p.m. ET. This is an input window, not a new certification deadline or practice mandate. Policy relevance: future USCDI expansion can become EHR build, data-capture, and data-quality work, so feedback should demand clinically validated use cases, phased adoption, mature implementation guidance, and vendor accountability for workflow and cost. Prepare: finish the Version 7 delta review and decide on a focused submission before the deadline. Sources: ONC, “United States Core Data for Interoperability,” USCDI v7 section (https://isp.healthit.gov/united-states-core-data-interoperability-uscdi#uscdi-v7) and official deadline reminder, Sept. 18, 2026 (https://x.com/ONC_HealthIT/status/2101052066747576467).

NIST and NIBIB are building a medical-metrology roadmap, with a small but immediate doorway into the room. Their RFI covers measurements and consensus standards for medical imaging, devices, diagnostics, and therapy. The September 24 symposium is nonbinding, but virtual registration closes tomorrow, September 22, at 5 p.m. ET; written comments are due November 30 at 11:59 p.m. ET. Physician policy angle: clinically meaningful standards should improve diagnostic reliability without shifting validation, procurement, reporting, or liability work onto practices. Monitor: decide today whether to register a virtual attendee, then scope whether the RFI merits comments on clinical validity, interoperability, human factors, and developer responsibility. Source: NIST/NIBIB, “Request for Information on Future Needs for Medical Metrology and Standards,” 91 FR 59111, Sept. 18, 2026 (https://www.federalregister.gov/documents/2026/09/18/2026-19147/request-for-information-rfi-on-future-needs-for-medical-metrology-and-standards-for-medical-imaging) (docket 260909-0004; Regulations.gov search NIST-2026-0133).

Signal Scan

The cached X scan was partial with findings. Its CMS/ONC-first lane succeeded and surfaced ONC’s official deadline reminder; the congressional topic timed out, so no congressional social signal was incorporated. No generic platform chatter changed the strategic picture.

Policy Action Implications

  • Complete the USCDI v7 burden-and-workflow delta and make a submission decision before September 28.
  • Build a GENEROUS implementation map before September 30, focusing on coverage, formulary, managed-care, and prior-authorization consequences.
  • Decide today whether to register for the NIST/NIBIB symposium; if yes, use it to frame a narrow November RFI response on clinical validity and accountable technology implementation.

Read more